Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype.

Carcinogenesis - 1 Aug 2007

El Touny Lara H, Banerjee Partha P

Abstract excerpt

Anti-proliferative properties of genistein in prostate and other cancers have been studied extensively. However, the identification of genistein targets that may mediate its chemopreventive effects in vivo requires further elucidation. In this study, we have demonstrated that the incorporation of genistein in the diet of transgenic adenocarcinoma mouse prostate model (TRAMP/FVB) mice resulted in a reduction in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Dietary Supplements
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Delivery Systems

Share to Genistein

Share to Glycogen Synthase Kinase 3

Share to Prostatic Neoplasms

Share to Proto-Oncogene Proteins c-akt

Source

Identifiers

PMID: 17468512
DOI: 10.1093/carcin/bgm103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype.PMID 17468512Read ↗

Suppression of Akt1-β-catenin pathway in advanced prostate cancer promotes TGFβ1-mediated epithelial to mesenchymal transition and metastasis.Semantic proximity Read ↗

Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.Semantic proximity Read ↗

Akt-regulated pathways in prostate cancerSemantic proximity Read ↗

Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies.Semantic proximity Read ↗

Differential impact of PI3K/AKT/mTOR signaling on tumor initiation and progression in animal models of prostate cancer.Semantic proximity Read ↗

Targeting the AKT protein kinase for cancer chemopreventionSemantic proximity Read ↗

Gata3 antagonizes cancer progression in Pten-deficient prostatesSemantic proximity Read ↗

Regression of Mouse Prostatic Intraepithelial Neoplasia by Nonsteroidal Anti-inflammatory Drugs in the Transgenic Adenocarcinoma Mouse Prostate ModelSemantic proximity Read ↗

The TGF-β, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancerSemantic proximity Read ↗

A constitutively activated form of the p110β isoform of PI3-kinase induces prostatic intraepithelial neoplasia in miceSemantic proximity Read ↗

Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.Semantic proximity Read ↗

Physiologically achievable concentrations of genistein enhance telomerase activity in prostate cancer cells via the activation of STAT3Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.